Aethlon Medical Files 2024 10-K

TL;DR

Aethlon Medical filed its 2024 10-K. Financials for FY ending March 31, 2024, are in.

AI Summary

Aethlon Medical, Inc. filed its 10-K for the fiscal year ending March 31, 2024. The company, formerly known as Bishop Equities Inc., is based in San Diego, CA. The filing covers the period from April 1, 2023, to March 31, 2024, and includes financial data for the fiscal years ending March 31, 2024, March 31, 2023, and March 31, 2022.

Why It Matters

This 10-K filing provides a comprehensive overview of Aethlon Medical's financial performance and business operations for the past fiscal year, which is crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a medical device company, Aethlon Medical faces inherent risks related to product development, regulatory approvals, and market adoption, which are typical for the industry.

Key Numbers

• 2024 — Fiscal Year End (The 10-K covers the fiscal year ending March 31, 2024.)
• 2023 — Fiscal Year End (The 10-K includes comparative financial data for the fiscal year ending March 31, 2023.)
• 2022 — Fiscal Year End (The 10-K includes comparative financial data for the fiscal year ending March 31, 2022.)

Key Players & Entities

• Aethlon Medical, Inc. (company) — Filer of the 10-K
• Bishop Equities Inc. (company) — Former name of Aethlon Medical, Inc.
• San Diego, CA (location) — Business address of Aethlon Medical, Inc.
• March 31, 2024 (date) — Fiscal year end for the reported 10-K
• 0001683168-24-004530 (filing_id) — Accession number for the 10-K filing

FAQ

Key Financial Figures

• $0.001 — T: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAM
• $2.258 — osing sale price of the common stock of $2.258 per share on the Nasdaq Capital Market

Filing Documents

• aethlon_i10k-033124.htm (10-K) — 1268KB
• aethlon_ex2101.htm (EX-21.1) — 2KB
• aethlon_ex2301.htm (EX-23.1) — 2KB
• aethlon_ex3101.htm (EX-31.1) — 9KB
• aethlon_ex3201.htm (EX-32.1) — 4KB
• aethlon_ex9701.htm (EX-97.1) — 40KB
• 0001683168-24-004530.txt ( ) — 5475KB
• aemd-20240331.xsd (EX-101.SCH) — 36KB
• aemd-20240331_cal.xml (EX-101.CAL) — 53KB
• aemd-20240331_def.xml (EX-101.DEF) — 150KB
• aemd-20240331_lab.xml (EX-101.LAB) — 344KB
• aemd-20240331_pre.xml (EX-101.PRE) — 293KB
• aethlon_i10k-033124_htm.xml (XML) — 673KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 15 Item 1B. Unresolved Staff Comments 45 Item 1C. Cybersecurity 45 Item 2.

Properties

Properties 46 Item 3.

Legal Proceedings

Legal Proceedings 47 Item 4. Mine Safety Disclosures 47 PART II . Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 Item 6. [ Reserved ] 48 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 48 Item 7A.

Quantitative and Qualitative Disclosures

Quantitative and Qualitative Disclosures about Market Risk 57 Item 8.

Financial Statements and

Financial Statements and Supplementary Data 57 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 57 Item 9A.

Controls and Procedures

Controls and Procedures 57 Item 9B. Other Information 59 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 59 PART III . Item 10. Directors, Executive Officers and Corporate Governance 60 Item 11.

Executive Compensation

Executive Compensation 60 Item 12.

Security Ownership of Certain Beneficial

Security Ownership of Certain Beneficial 60 Item 13. Certain Relationships and Related Transactions, and Director Independence 60 Item 14. Principal Accountant Fees and Services 60 PART IV . Item 15. Exhibits and Financial Statement Schedules 61 Item 16. Form 10-K Summary 64

Signatures

Signatures 65 i CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K, or Annual Report, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Annual Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of future regulatory filings, the timing and results of future clinical trials, and capital outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statement of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could

BUSINESS

ITEM 1. BUSINESS Unless otherwise indicated or the context otherwise requires, references to the "Company", "Aethlon", "we", "us" and "our" refer to Aethlon Medical, Inc. Overview and Corporate History Overview We are a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a "Breakthrough Device" for two independent indications: the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and the treatment of life-threatening viruses that are not addressed with approved therapies. Oncology We believe the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently working with our contract resea

View Full Filing

View this 10-K filing on SEC EDGAR